Trusted Resources: News & Meetings

Latest announcements and gatherings

Burosumab May Improve Multiple Clinical Outcomes in X-Linked Hypophosphatemia


Burosumab, a fully human monoclonal antibody against fibroblast growth factor 23 (FGF23), may restore phosphorus homeostasis and improve mineralization defect in in patients with X-linked hypophosphatemia (XLH), according to study results published in the Journal of Bone & Mineral Research.

Loss-of-function mutations in the PHEX gene (phosphate-regulating endopeptidase homolog, X-linked) cause XLH, a rare disease associated with increased FGF23 levels, chronic hypophosphatemia, and impaired production of 1,25-dihydroxyvitamin D. Burosumab was approved for the treatment of XLH, with studies reporting improved fracture healing and increased serum phosphorus levels and bone remodeling markers.

An ongoing open-label phase 3 single-group multicenter trial is investigating the efficacy of burosumab in improving osteomalacia in adults with XLH.

 

Burosumab May Improve Multiple Clinical Outcomes In X-Linked Hypophosphatemia

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close